The onset of stroke affects the gut microbiota, while the gut microbiota also promotes the development of stroke. Although we have already known that the gut microbiota plays an important role in stroke, the exact mechanism of action needs to be studied in more depth. In response to this phenomenon, Ace Therapeutics offers a comprehensive service to explore in depth the role of the gut microbiota in the development of stroke.
Microbial signaling molecules include bacterial structural components and metabolites of the intestinal microbiota, which can affect the intestinal ecology and intestinal barrier function, even can induce complications and promote the worsening of stroke. With this in mind, Ace Therapeutics offers a comprehensive service to explore the role of microbial signaling molecules in stroke.
Many clinical studies have verified that stroke patients often present with symptoms of gut dysbiosis. In view of this, Ace Therapeutics provides a different approach to investigating the altered gut microbiota in stroke model animals. We assessed the impact of stroke on the gut microbiota ecology at different levels.
Stroke attacks can lead to neuroinflammation and immune response. As a major organ of the immune response, the digestive tract regulates the pathological process of stroke through the microbiota-gut-brain axis. Therefore, Ace Therapeutics provides a comprehensive service to promote the understanding of the role of the microbiota-gut-brain axis in the stroke process.
We evaluate the effects of stroke-induced inflammation and immune response on the gut microbiota by measuring the number and distribution of cytokines, the number and distribution of immune cells, the levels of blood biomarkers, and the number and distribution of damage signals released by dying cells from the ischemic core and peri-infarct areas.
If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.